QGEN — Qiagen N.V. Common Shares
Session close: $50.22. Regular-session share volume: 34,862,041. Change from previous close: +0.44%.
Key developments
Qiagen agreed to an all-cash acquisition by EQT at a premium to its share price before takeover reports emerged. Both boards unanimously endorsed the deal, citing certain cash returns for shareholders and greater flexibility for long-term investment under private ownership. The transaction remains pending, with regulatory approvals still relevant to closing.
Long-Awaited Qiagen Buyout Closes At 15x EBITDA Multiple as Slow Growth Curbs Pricing · QIAGEN Agrees to Acquisition by EQT for $12.1 Billion
Qiagen also suspended its full-year outlook, alongside preliminary quarterly results released after the prior session. William Blair described uneven portfolio growth and weaker immigration-related tuberculosis testing demand as reasons for a lower valuation than comparable deals. JPMorgan downgraded the shares from Overweight to Neutral and lowered its target; Berenberg raised its target following the acquisition agreement but retained Hold.
Long-Awaited Qiagen Buyout Closes At 15x EBITDA Multiple as Slow Growth Curbs Pricing · This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday · Berenberg Adjusts Price Target for QIAGEN · QIAGEN reports preliminary Q3 2026 results